Month: June 2026

Introduction and Objective: AT7687 is a first-in-class peptide GIPR antagonist validated as anti-obesity therapy in obese monkeys, as monotherapy and in combination with liraglutide and cagrilintide. This randomized, double-blind, placebo-controlled study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics of AT7687 (AT).Methods: In the single ascending dose (SAD) part, 60 participants randomized 6:2 by cohort received […]

Introduction and Objective: We tested the hypothesis that tirzepatide (TZ), a dual GLP-1/GIP agonist, improves metabolic health independent of weight loss via GIP effects on adipose cells. Dual GLP-1/GIP agonists are known to lower blood glucose to a greater degree than selective GLP-1 agonists. We quantified insulin resistance (IR) and adipose cell function after 6 […]

Introduction and Objective: Early type 1 diabetes (T1D) detection is vital to prevent DKA, which affects 60% of pediatric cases. However, traditional screening relies on invasive blood draws, limiting accessibility for young children. We launched the first “fully remote” T1D screening program designed for large-scale implementation using a novel genetic stratification tool alongside online monitoring […]

Introduction and Objective: Food Is Medicine interventions are being promoted to improve glycemic control in type 2 diabetes mellitus (T2D), but limited randomized trial (RCT) data exist. We evaluated the efficacy of a scalable, technology-based grocery prescription program in low-income, high-risk adults with T2D.Methods: We conducted a 1:1 RCT in Kaiser Permanente Northern & Southern […]

Introduction and Objective: Food insecurity leads to worse type 2 diabetes (T2D) outcomes, but which food insecurity intervention best improves T2D outcomes is unclear. Our objective was to compare the effectiveness of two food insecurity interventions: medically tailored meals (MTM) and food subsidies.Methods: Randomized comparative effectiveness trial (NCT04828785). Adults with T2D and food insecurity received […]

Introduction and Objective: Diabetes damages retinal mitochondria and impairs their removal by mitophagy, and these damaged mitochondria continue to accumulate. Diabetes also results in aberrant expression of many long noncoding RNAs (LncRNAs), the RNA transcripts with >200 nucleotides. These noncoding RNAs can interact with RNA, DNA and proteins, regulating many physiological processes. Among them, LncRNA […]

Introduction and Objective: Irisin is a hormone secreted by skeletal muscle following physical activity or exposure to excess saturated fatty acids, promoting energy expenditure and insulin secretion. Circulating irisin levels are reduced in patients with type 2 diabetes (T2D), while exogenous irisin administration improves glycemic control in diabetic mice. Interestingly, irisin and GLP-1 share pleiotropic […]

Introduction and Objective: We compared perinatal outcomes among pregnancies complicated by type 2 diabetes (T2D) managed with continuous glucose monitoring (CGM) to self-monitored blood glucose (SMBG).Methods: Patients with pre-pregnancy T2D, singleton gestation, and delivery between 2018-2024 at two health systems were identified by ICD-10 codes. Patient demographics and outcomes were abstracted and compared between those […]

Introduction and Objective: Many people living with T1D do not achieve glycemic targets, and the risk of severe hypoglycemia persists. HDV-L restores postprandial hepatic glycogen storage by presenting insulin to hepatocyte receptors as a dense molecular aggregate, improving receptor signaling. The OPTI-2 study evaluated the impact of HDV-L on A1C and hypoglycemia risk.Methods: In a […]